DOCSLIB.ORG

Introduction to Medicinal Chemistry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction to Medicinal Chemistry MC: Gonadal Hormones & Inhibitors Required reading W & G 12th Ed, page 819-864 Reference Foye's 7th Ed, Page 1346-1434 PHRM 614-P2 Shengquan Liu Ph. D 12-06-18, Th, AM, Rm 170 File name: EPA_181206aTh/12-03 1 MoA Review (14 Classes & 32 Drugs) Female: Ovary Male: Testis Antagonist: ganirelix & cetrorelix “-relix” ↓ ovarian hyperstimulation Agonist: “-relix” ↓ PC Leuprolide ↓ FSH/LH ↓ E/A (-) E® ↑ FSH/LH (+) ovulation ↓ FSH/LH (-) P450 & (-) E/A ® (-) P450 ↓ [EPA] ↓ PC (-) P450 & E/A® ↓ BPH/alopecia ↓ E®+ BC 5-1: 5-3: 5-1: ↓ PC ↓ E®+ BC 5-3: (-) A/M® ↓ hirsutism 2 Learning Objectives: Chemical Structures 1. Biosynthesis & metabolism of 3 natural sex hormones (endogenous ligands, E, P & T) – Native hormones are orally inactive & short-lived rapid metabolism ↓ F/t1/2/DoA (-) metabolism ↑ F/t1/2/DoA new drug designs 2. Metabolism of major drugs & its relations to 1. Bioavailability, DoA & SAR 2. Prodrugs 3. Pharmacophore & SAR related to 1. MoA/site (tissues) of action, indication & SEs 2. Potency/selectivity (agonists & antagonists) 3. Oral activity & DoA 4. Recognize chemical structures of major drugs – structure ↔ name ↔ drug classification ↔ MoA ↔ indication/SE drug selection & clinical decision 3 Gonadal Hormones & Inhibitors (32): Outline 1. Ovarian hormones (“female sex hormones”) 1. Estrogens & antiestrogens ↑ or ↓ E action respectively 1. Estradiol (E2), ethinyl estradiol & other estrogens (+) E® 2. Antiestrogens (±) or (-) E®; AIs (-) aromatase ↓ [E] 1. SERMs (tamoxifen) (±) E® (±) or (-) E® ↓ E®+ BC 2. Pure antagonist: fulvestrant (-) E® 3. Aromatase inhibitors (AIs, anastrozole) (-) aromatase ↓ [E] ↓ E®+ BC 2. Progestins & antiprogestins ↑ or ↓ P action respectively 1. Progesterone (“pregnancy hormone”), norgestrel & its analogs (+) P® 2. Antiprogestins (mifepristone) (-) P® abortion 2. Testis hormones (“male sex hormone”) – Androgens & antiandrogens ↑ or ↓ A action respectively 1. Testosterone (T) & its analogs (+) A® ↑ A action – 5a-dihydrotestosterone (DHT, a more potent metabolite) 2. Antiandrogens ↓ A action – A® antagonists (flutamide) (-) A® ↓ PC – 5a-Reductase inhibitors (finasteride*) ↓ [DHT] ↓ BPH/hirsutism – Synthesis inhibitors (ketoconazole) (-) CYP ↓ [E, P or A] 4 Biosynthesis of Sex Hormones Acetate What is MoA of: 1. Ketoconazole 2. Anastrozole 3. Finasteride (DHEA) 5a-reductase DHT Hormonal Control of the Female Reproductive System 6 1. Natural Sex Hormones (Remember) Steroids that are necessary for reproduction in females & males & affect the development of 2nd sex characteristics – Progesterone (P) precursor to testosterone, estrogens, cortisol & aldosterone – Testosterone (T) Precursors of estrogens T 5a-Dihydrotestosterone (DHT, 10 X more active than T) – Estradiol (E2) 7 1. Natural Ovarian (Female) Hormones Structure 18 Cs 21 Cs 3-,17-di-OH (E2) 17-acetyl Aromatic A ring 3-keto/4-ene A ring Class Estrogens Progestins Released by Follicle in ovary Corpus luteum in ovary Functions 2nd sex characteristics For pregnancy Uses hypoGonad/HRT, OC, osteoporosis HRT/infertility/OC Effects on heart ↓ LDL, ↑ HDL/TG/Thrombosis* ↑ LDL/TG, ↓ HDL, Risk of BC or ↑ ↓ endometrial CA Higher concentration in females * Deep Vein Thrombosis (DVT). 8 1. Ovarian (Female) Hormones: Estrogens Nature Reviews Endocrinology 7, 715-726 (December 2011) 9 3 Endogenous Estrogens: Ph, 3- & 17-di-O(H) # of OH FG 1 2 3 Potency 1 10 (most potent) very weak In circulation (%) 60-80 10-20 10-20 In urine Conjugates Uses HRT HRT HRT (rare) An extract of ovaries can produce estrus (1932) All are 18 Cs, 3-OH & 17-OH (or keto), phenolic A ring (for binding w/ E®) Uses: estrogen component in HRT Many phenols are estrogenic 10 1.1. Metabolism in Liver F-: Major Pathway 16a-hydroxylation & 17-OH oxidation in D ring – Minor pathway: 2-, or 4-hydroxylation 2- or 4-O-methylation (COMT) Metabolism mainly in liver & largely excreted as glucuronide & sulfate conjugates in urine or bile (enterohepatic circulation) SEs: ↑ clotting factor synthesis To avoid these SEs, use vaginal, transdermal or injection form11 1.1. Steroidal Estrogens: Estradiol (3,17-OH) Uses: hypogonadism/HRT & contraceptives F-/PO+ formulations: – Micronized form (PO) for menopause ↑ absorption – I.M. injection st – Transdermal patch for menopause No 1 pass metabolism Less DVT risk – Vaginal cream/ring Lipophilic high protein binding High affinity for E®s high potency parenterally, but Poor oral bioavailability (F ≈ 5%) due to: – 3-OH-conjugation in intestine & metabolic oxidation of 17-OH in liver ↓ oral activity & elimination t1/2 20 min. Can we design longer-acting or more orally active drugs & how ? Think about 3 &17-OH – 3 methods 12 1.1. 17b-Estradiol Esters (IM) ↑ DoA 17-Ester prodrug IM (in oil) for long-term therapy Slowly hydrolyzed to estradiol in vivo long-acting – ↑ R size ↑ log P & more hindered ↓ absorption rate ↑ DoA – Tx: hypogonadism in girls or women 13 Ethinyl Estradiol* (EE, 17a-C≡CH PO, OCs) (-) metabolic inactivation ↑ F/t1/2/DoA – 17b-OH metabolism was blocked & permanently protected w/ 17a-ethynyl group – ↑ potency (200 X more potent than estradiol) Use: Combined oral contraceptive (COC)/HRT14 Ethinyl Estradiol (EE) Metabolism: 2, 3-OMe Use: COC – Like many other OCs, 3A4 substrate DDIs – 3-O-glucuronide & -sulfate metabolites (inactive) Why some broad-spectrum antibiotics ↓ OC efficacy? – 3-O-methyl ether of EE = Mestranol 15 Mestranol (3-OCH3, COC) Ethinyl Estradiol A prodrug of EE – Synthetic estrogens, no 3-O-conjugation ↑ DoA Rapidly bioactived mainly to EE by hepatic O-demethylation following PO Both mestranol & ethinyl estradiol are used primarily in COC Please compare these 2 drugs Can you use mestranol locally? 16 1.1. Conjugated Estrogens: Water-Soluble Equilin & equilenin (equine = horse) – Obtained from Pregnant mares’ urine as “Premarin* or conjugated estrogen for HRT Premarin: a mixture of sodium estrone sulfate, sodium equilin sulfate & sulfate conjugates of some metabolites Excreted in urine as sodium sulfate conjugates – Water-soluble metabolites of natural estrogens Conjugated Estrogens USP is a mixture of sodium salts of sulfate esters of estradiol derived from equine urine or prepared synthetically from estrone & equilin 17 1.1. Nonsteroidal Estrogens: Stilbenes The steroid nucleus is NOT required for activity (B & C rings can open) Some stilbene (diphenylethylene) drugs – trans isomers are more stable & potent than cis isomers Diethylstilbestrol (DES) – Never used in pregnancy, removed from US, only used in veterinary med now 18 1.1. SAR : General Important FGs 1. Aromatic A ring 1. Planar hydrophobic scaffold 2. Steroids w/ an aromatic A ring lack affinity to other steroid hormone ®s 2. 3 & 17b-OH (2 HBDs) 3. Distance between 3-OH & 17-OH groups ≈ 10.3-12.1 Å 19 1.1. Steroid Hormone: MOA 2 HBDs 20 1.1. SAR : Substituents Aromatic A ring, 3 & 17-OH are important SAR is often in PCOA exam! 21 1.1. Estrogens: Same MoA & Different PK Uses \ Drugs E2 Estrogen esters EE: Orally active Conjugates (IM) estrogens equine estrogens PO Poor oral activity ↑ DoA ↑ F/t1/2/DoA /potency Retain some activity Short t1/2/DOA (e.g. equilin sodium sulfate) Metabolism 1st-pass metabolism Slowly hydrolyzed to E2 Resistance to 1st-pass Conjugation hepatic metabolism Metabolic conjugates retain some activity (e.g. equilin sodium sulfate) Hypogonadism + HRT E1, 2 & 3 ++ ++ OC +++ Potency ++ ++++ 200X vs. E2 + 22 Estrogen: Estradiol: MoA Rapid uptake & retained more in breast, uterus & vagina 2 main estrogen ®s – ERa: mainly in female reproductive tract & mammary glands – ERb: mainly in vascular endothelial cells, bone & male prostate tissues – Estradiol has similar affinities for both ERs Certain non-steroidal estrogens & antiestrogens are different ® binding estradiol-® complex – Conformation change of the ®s homo or heterodimers – Interacts w/ estrogen response elements (ERE) of cellular DNA – DNA transcription mRNA protein synthesis Regulation of gene expression & protein synthesis 23 Estrogens: Estradiol & Breast Cancers (FYI) (+) gene expression ↑ production of several proteins – Intracellular proteins important for breast cell function & growth Enzymes needed for DNA synthesis – DNA polymerase, dihydrofolate reductase …… – Proteins that influence tumor growth & metastasis Transforming growth factor-a (TGFa) & TGFb Insulin-like growth factor I (IGF-I) Cathepsin D protein: (+) breast cancer cell metastasis So, ↑↑ estrogens can (+) proliferation of breast cells & causes estrogen-dependent breast cancer (ER+ BC) – ↑ growth of hormone-dependent mammary carcinoma 24 2.2. Antiestrogens: BCs & Ovarian Cancers Estrogen is a growth factor for ER+ BC cells (-) estrogen action ↓ ER+ BC Tx: ER+ BC & infertility 3 groups 1. Triphenylethylene antiestrogens (±) ERs • Selective estrogen receptor modulators (SERMs) • Act as estrogen agonist in some tissues, partial agonists or estrogen antagonists in other tissues tissue-specific 2. Pure antagonists 3. (-) aromatase ↓ estrogen (E) biosynthesis ↓ [E] ↓ BC 25 SERMs: Triphenylethylenes Antiestrogens Tamoxifen: High affinity for ERs Produce antiestrogen-® complexes that – Prevent translocation of E-® complex into nucleus of target cells – (-) binding of E-® complex to estrogen response elements (ERE) of cellular DNA Toremifene (Cl): similar structure/property/indication & toxicity to tamoxifen, but – Beneficial effects on bone, CV & HDL 26 1st G. SERM (Triphenylethylenes): Tamoxifen* Antagonist on breasts prevent or treat E®+ BC Antagonist on CNS hot flash Agonist on
Load more

Recommended publications
  • Wo 2009/082437 A9
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 July 2009 (02.07.2009) WO 2009/082437 A9 (51) International Patent Classification: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, C07D 207/08 (2006.01) A61K 31/402 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, C07D 207/09 (2006.01) A61P 5/26 (2006.01) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, C07D 498/04 (2006.01) SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US2008/013657 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: G M M N S D S L s z τ z U G Z M 12 December 2008 (12.12.2008) z w Eurasian (A M B γ KG> M D RU> τ (25) Filing Language: English TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English M C M T N L N O P L P T R O S E S I s T R OAPI (30) Priority Data: B F ' B J ' C F ' C G ' C I' C M ' G A ' G N ' 0 G W ' M L ' M R ' 61/008,731 2 1 December 2007 (21 .12.2007) US N E ' S N ' T D ' T G ) - (71) Applicant (for all designated States except US): LIG- Declarations under Rule 4.17: AND PHARMACEUTICALS INCORPORATED [US/ — as to applicant's entitlement to apply for and be granted US]; 11085 N.
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • The Effects of Androgens and Antiandrogens on Hormone Responsive Human Breast Cancer in Long-Term Tissue Culture1
    [CANCER RESEARCH 36, 4610-4618, December 1976] The Effects of Androgens and Antiandrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture1 Marc Lippman, Gail Bolan, and Karen Huff MedicineBranch,NationalCancerInstitute,Bethesda,Maryland20014 SUMMARY Information characterizing the interaction between an drogens and breast cancer would be desirable for several We have examined five human breast cancer call lines in reasons. First, androgens can affect the growth of breast conhinuous tissue culture for andmogan responsiveness. cancer in animals. Pharmacological administration of an One of these cell lines shows a 2- ho 4-fold stimulation of drogens to rats bearing dimathylbenzanthracene-induced thymidina incorporation into DNA, apparent as early as 10 mammary carcinomas is associated wihh objective humor hr following androgen addition to cells incubated in serum regression (h9, 22). Shionogi h15 cells, from a mouse mam free medium. This stimulation is accompanied by an ac many cancer in conhinuous hissue culture, have bean shown celemation in cell replication. Antiandrogens [cyproterona to be shimulatedby physiological concentrations of andro acetate (6-chloro-17a-acelata-1,2a-methylena-4,6-pregna gen (21), thus suggesting that some breast cancer might be diene-3,20-dione) and R2956 (17f3-hydroxy-2,2,1 7a-tnima androgen responsive in addition to being estrogen respon thoxyastra-4,9,1 1-Inane-i -one)] inhibit both protein and siva. DNA synthesis below control levels and block androgen Evidence also indicates that tumor growth in humans may mediahed stimulation. Prolonged incubahion (greahenhhan be significantly altered by androgens. About 20% of pahianhs 72 hn) in antiandrogen is lethal.
    [Show full text]
  • Alpha-Fetoprotein: the Major High-Affinity Estrogen Binder in Rat
    Proc. Natl. Acad. Sci. USA Vol. 73, No. 5, pp. 1452-1456, May 1976 Biochemistry Alpha-fetoprotein: The major high-affinity estrogen binder in rat uterine cytosols (rat alpha-fetoprotein/estrogen receptors) JOSE URIEL, DANIELLE BOUILLON, CLAUDE AUSSEL, AND MICHELLE DUPIERS Institut de Recherches Scientifiques sur le Cancer, Boite Postale No. 8, 94800 Villejuif, France Communicated by Frangois Jacob, February 3, 1976 ABSTRACT Evidence is presented that alpha-fetoprotein nates in hypotonic solutions, whereas in salt concentrations (AFP), a serum globulin, accounts mainly, if not entirely, for above 0.2 M the 4S complex is by far the major binding enti- the high estrogen-binding properties of uterine cytosols from immature rats. By the use of specific immunoadsorbents to ty. AFP and by competitive assays with unlabeled steroids and The relatively high levels of serum AFP in immature rats pure AFP, it has been demonstrated that in hypotonic cyto- prompted us to explore the contribution of AFP to the estro- sols AFP is present partly as free protein with a sedimenta- gen-binding capacity of uterine homogenates. The results tion coefficient of about 4-5 S and partly in association with obtained with specific anti-AFP immunoadsorbents (12, 13) some intracellular constituent(s) to form an 8S estrogen-bind- provided evidence that at low salt concentrations,'AFP ac-' ing entity. The AFP - 8S transformation results in a loss of antigenic reactivity to antibodies against AFP and a signifi- counts for most of the estrogen-binding capacity associated cant change in binding specificity. This change in binding with the 4-5S macromolecular complex.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • BRS Pharmacology
    Pharmacology Gary C. Rosenfeld, Ph.D. Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences Assistant Dean for Education Programs University of Texas Medical School at Houston Houston, Texas David S. Loose, Ph.D. Associate Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences University of Texas Medical School at Houston Houston, Texas With special contributions by Medina Kushen, M.D. William Beaumont Hospital Royal Oak, Michigan Todd A. Swanson, M.D., Ph.D. William Beaumont Hospital Royal Oak, Michigan Acquisitions Editor: Charles W. Mitchell Product Manager: Stacey L. Sebring Marketing Manager: Jennifer Kuklinski Production Editor: Paula Williams Copyright C 2010 Lippincott Williams & Wilkins 351 West Camden Street Baltimore, Maryland 21201-2436 USA 530 Walnut Street Philadelphia, PA 19106 All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner. The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers’ product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions. Printed in the United States of America Library of Congress Cataloging-in-Publication Data Rosenfeld, Gary C. Pharmacology / Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Norgestrel and Gestodene Stimulate Breast Cancer Cell Growth Through an Oestrogen Receptor Mediated Mechanism
    Br. J. Cancer (1993), 67, 945-952 '." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 67, 945-952 1993 Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism W.H. Catherino, M.H. Jeng & V.C. Jordan Department ofHuman Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Summary There is great concern over the long-term influence of oral contraceptives on the development of breast cancer in women. Oestrogens are known to stimulate the growth of human breast cancer cells, and this laboratory has previously reported (Jeng & Jordan, 1991) that the 19-norprogestin norethindrone could stimulate the proliferation of MCF-7 human breast cancer cells. We studied the influence of the 19-norprogestins norgestrel and gestodene compared to a 'non' 19- norprogestin medroxyprogesterone acetate (MPA) on MCF-7 cell proliferation. The 19-norprogestins stimulated proliferation at a concentration of 10-8 M, while MPA could not stimulate proliferation at concentrations as great as 3 x 10-6 M. The stimulatory activity of the 19-norprogestins could be blocked by the antioestrogen ICI 164,384, but not by the antiprogestin RU486. Transfection studies with the reporter plasmids containing an oestrogen response element or progesterone response element (vitERE-CAT, pS2ERE-CAT, and PRE15-CAT) were performed to determine the intracel- lular action of norgestrel and gestodene. The 19-norprogestins stimulated the vitERE-CAT activity maximally at 10-6 M, and this stimulation was inhibited by the addition of ICI 164,384. MPA did not stimulate vitERE-CAT activity. A single base pair alteration in the palindromic sequence of vitERE (resulting in the pS2ERE) led to a dramatic decrease in CAT expression by the 19-norprogestins, suggesting that the progestin activity required specific response element base sequencing.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Supplementary Tables, Figures and Other Documents
    Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]